Why Tango Therapeutics (TNGX) Is Back In The Spotlight
Tango Therapeutics (TNGX) drew fresh attention after reporting Phase 1/2 data for vopimetostat combinations in MTAP-deleted, RAS-mutant PDAC and NSCLC, along with plans for a global front-line pancreatic cancer trial.
After a huge year-to-date share price return of 154.31% and a 1-year total shareholder return of 180.02%, Tango Therapeutics now trades at US$22.71. The recent 30-day share price return is down 8.98% and the 90-day share price return is down 16.45%, suggesting momentum has cooled even as enthusiasm around the pipeline and clinical updates remains a key driver of sentiment.
Scan other oncology-focused opportunities that are moving on clinical catalysts with our curated list of 19 high quality undiscovered gems, which share Tango Therapeutics' mix of high science and early-stage potential.
After a huge swing higher and a cooler patch in recent weeks, Tango Therapeutics now forces a simple choice. Do you commit at today’s price, or wait in case enthusiasm and valuation reset further?
Most Popular Narrative: 52% Undervalued
Tango Therapeutics screens as materially below the most followed fair value estimate of $47.09, compared with the last close at $22.71, which puts the focus squarely on whether vopimetostat can carry that gap.
The main thing that has to go right is for vopimetostat based regimens, including RAS inhibitor combinations, to convert strong response and PFS data into successful late-stage trials in competitive indications like pancreatic cancer.
The current valuation, including a stock price that has risen around 7 to 8 times over the past year alongside multiple Buy or Overweight ratings and higher price targets, implies that the market is pricing in meaningful commercial potential for the vopimetostat franchise.
See why 1 investors see Tango Therapeutics as 52% undervalued.
Result: Fair Value of $47.09 (UNDERVALUED)
Still, the Tango Therapeutics story hinges on vopimetostat delivering in tough pancreatic cancer trials. Any disappointing data or delays could quickly unwind the current valuation narrative.
Find out about the key risks to this Tango Therapeutics narrative.
Another View: Tango Therapeutics Through The P/B Lens
The analyst fair value of $47.09 paints Tango Therapeutics as undervalued. Yet on a simple P/B basis the stock trades at 3.7x, which is richer than the US Biotechs average of 2.0x and only looks cheap against closer peers at 4.9x. That mix hints at valuation risk if sentiment cools, so which reference point matters more to you?
See what the numbers say about this price gap in our detailed breakdown, starting with See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed views on Tango Therapeutics so far. If you want a firm handle on both upside and downside, start with the 1 key reward and 3 important warning signs.
Looking for more Tango Therapeutics style ideas?
If Tango Therapeutics has your attention, do not stop here. Broader opportunity often sits just beyond the one headline that drew you in today.
- Target resilient balance sheets and steady fundamentals by scanning the list of solid balance sheet and fundamentals (24 results) that could handle pressure when conditions get tougher.
- Zero in on stronger value setups by working through the 33 high quality undervalued stocks that pair more attractive pricing with quality fundamentals.
- Round out your watchlist with income-focused candidates by reviewing the 5 dividend fortresses built around higher-yield payouts and staying power.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com